Embecta (NYSE: EMBC) CEO Dev Kurdikar says the company set out for its second full year since spinning off from BD with three clear goals.
The company wanted to keep the core business strong, continue progressing on the separation and standing on its own and, finally, continue investing in growth — namely on its insulin patch pump development program.
Embecta’s core business continued to grow, completed a number of crucial projects related to the separation and continued the development of the patch pump with new partnerships and more.
“For now I’ll say I’m very pleased with our progress,” Kurdikar told Drug Delivery Business News. “We’ve continued exactly on the path that we laid out more than two years ago, now. We saw substantive progress in 2023. For 2024, it’s the same priorities, but we’re looking forward to getting closure on a few of these things.”
Just before the spin became official, Kurdikar laid out why the move enhanced the pure-play diabetes company’s business. At the start of this year, he explained to DDBN how the company started strong and what was still to come.
Now, as the company progresses — and the diabetes landscape undergoes some massive changes — Kurdikar offered insight into where Embecta is heading.
“When you first ring that bell on opening day, when the documentation of the spin is complete and the shares have been distributed to the new shareholders — that’s really the starting point of all the hard work that the teams have to do,” Kurdikar said.
Get the full story at our sister site, Drug Delivery Business News.
